Fracture
- 28 Nov 2023
- 2 Minutes to read
- Print
- PDF
Fracture
- Updated on 28 Nov 2023
- 2 Minutes to read
- Print
- PDF
Article summary
Did you find this summary helpful?
Thank you for your feedback
OSTEOPOROSIS
- Osteoporosis is characterised by reduced bone strength, predisposing to fracture.
- It affects 1 in 3 women, compared to 1 in 5 men.
- Bone loss itself does not cause any symptoms, and it is a silent process until fracture occurs.
- It is estimated that 1 in 2 women in the UK will suffer a fracture after the age of 50 years.
BONE LOSS AT MENOPAUSE
- In women, the menopause transition represents a time of increased bone loss.
- Research from SWAN, which is a large longitudinal study, indicates that resorption begins around 2 years before the final menstrual period, peaks approximately 1.5 years after the final period, and then plateaus.
- During this 3-year-long interval, the average rate of decline in bone mineral density in white women was 2.5% per year in the lumbar spine and 1.8% per year in the femoral neck.
- Changes in oestrogen levels appear to drive this bone loss. Oestrogen can alter the activity of osteoclasts, osteoblasts and osteocytes, with the principal effects as an antiresorptive agent through reduction of osteoclast numbers and function.
RISK ASSESSMENT
- Risk factors for osteoporosis should be assessed and advice on bone health given if indicated.
- The FRAX risk calculator tool gives a 10-year probability of hip or major osteoporotic fracture and can be used to aid decisions about when to give lifestyle advice alone, measure BMD, treat or consider specialist referral.
- The FRAX tool is not validated for women under 40 years.
References and Further Information:
- SWAN study. Greendale G, Sowers M, Han W et al. Bone mineral density loss in relation to the final menstrual period in a multi-ethnic cohort: Results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res 2012.
- Karlamangla A, Burnett-Bowie S, Crandall C. Bone health during the menopause transition and beyond. Obstet Gynaecol Clin North Am 2018.
- Osteoporosis: assessing the risk of fragility fracture. NICE guideline. Last updated 2017.
- Curtis EM, Moon RJ, Dennison EM, Harvey NC, Cooper C. Recent advances in the pathogenesis and treatment of osteoporosis. Clinical medicine (London, England) 2015;15(Suppl 6):s92–s96.
- Hamoda H, Panay N, Pedder H et al. The British Menopause Society and WHC 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health 2020.
- Khosla S, Oursler M, Monroe D. Estrogen and the skeleton. Trends Endocrinol Metab. 2012.
- Lorentzon M, Johansson H, Harvey N et al. Osteoporosis and fractures in women: the burden of disease. Climacteric. 2022.
- Stevenson J in collaboration with the medical advisory council of the British Menopause Society. Prevention and treatment of osteoporosis in women. Post Reprod Health. 2022.
Was this article helpful?